Genetic Technologies Ltd

Genetic Technologies Limited is a molecular diagnostics company that provides predictive genetic testing and risk assessment tools to help physicians manage health across the Americas, Canada, Europe, the Middle East, Africa, Latin America, and Asia Pacific. It operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer, and markets it to healthcare professionals in breast health and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists such as breast surgeons. It also offers cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brands, and develops tests for other diseases including ovarian, prostate, pancreatic, and colorectal cancers, melanoma, coronary artery disease, type 2 diabetes, and atrial fibrillation. Additionally, it provides genetic testing services for medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Memorial Sloan Kettering Cancer Center, the University of Cambridge, Harvard University, Ohio State University, and Washington University. Incorporated in 1987, it is headquartered in Prahran, Australia.